|
Mechanism53BP1 antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with University of North Carolina at Chapel Hill /Gene Mfg Ops/
0 Patents (Medical) associated with University of North Carolina at Chapel Hill /Gene Mfg Ops/
100 Deals associated with University of North Carolina at Chapel Hill /Gene Mfg Ops/
100 Translational Medicine associated with University of North Carolina at Chapel Hill /Gene Mfg Ops/